We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+1.2%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.79B
AUM Growth
-$552M
Cap. Flow
-$341M
Cap. Flow %
-19.04%
Top 10 Hldgs %
44.27%
Holding
146
New
11
Increased
19
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.9M
2
AGEN
Agenus
AGEN
+$27.2M
3
RVMD icon
Revolution Medicines
RVMD
+$21.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.3M
5
VOR icon
Vor Biopharma
VOR
+$11.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$53M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$47.9M
3
BLU
BELLUS Health Inc.
BLU
+$21.4M
4
ONC
BeOne Medicines Ltd
ONC
+$9.17M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$7.88M

Sector Composition

Rank Sector Weight
1 Healthcare 92.03%
2 Consumer Discretionary 3.74%
3 Real Estate 0.39%
4 Financials 0.33%
5 Industrials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAI
76
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$2.93M 0.16%
550,000
– –
PRAX icon
77
Praxis Precision Medicines
PRAX
$8.11B
$2.86M 0.16%
80,000
– –
CGEM icon
78
Cullinan Oncology
CGEM
$1.06B
$2.64M 0.15%
250,000
– –
OTLY
79
Oatly Group
OTLY
$476M
$2.61M 0.15%
75,000
– –
KRON
80
DELISTED
Kronos Bio
KRON
$2.5M 0.14%
1,542,954
– –
LYEL icon
81
Lyell Immunopharma
LYEL
$318M
$2.43M 0.14%
35,000
– –
FUSN
82
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.36M 0.13%
750,000
– –
ORIC icon
83
Oric Pharmaceuticals
ORIC
$1.17B
$2.36M 0.13%
400,000
– –
LENZ
84
LENZ Therapeutics
LENZ
$179M
$2.32M 0.13%
100,000
– –
STOK icon
85
Stoke Therapeutics
STOK
$1.84B
$2.31M 0.13%
250,000
– –
TRML
86
DELISTED
Tourmaline Bio
TRML
$2.11M 0.12%
206,426
– –
ACIU icon
87
AC Immune
ACIU
$231M
$2.04M 0.11%
1,000,000
– –
ACHL
88
DELISTED
Achilles Therapeutics
ACHL
$2.03M 0.11%
2,255,375
– –
YMAB
89
DELISTED
Y-mAbs Therapeutics
YMAB
$1.95M 0.11%
400,000
– –
BBIO icon
90
BridgeBio Pharma
BBIO
$16.4B
$1.91M 0.11%
250,000
– –
CYCN icon
91
Cyclerion Therapeutics
CYCN
$15.2M
$1.82M 0.1%
138,956
– –
CYPH
92
Cypherpunk Technologies Inc
CYPH
$64M
$1.8M 0.1%
400,000
– –
IMUX icon
93
Immunic
IMUX
$178M
$1.78M 0.1%
127,471
+57,471
+82% +$1.57M
IMMP
94
Immutep
IMMP
$56.1M
$1.75M 0.1%
1,000,000
– –
APTX
95
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.75M 0.1%
6,116,493
– –
SANA icon
96
Sana Biotechnology
SANA
$882M
$1.58M 0.09%
400,000
– –
HOOK
97
DELISTED
HOOKIPA Pharma
HOOK
$1.5M 0.08%
184,962
– –
ME
98
DELISTED
23andMe Holding Co
ME
$1.43M 0.08%
33,050
– –
IRWD icon
99
Ironwood Pharmaceuticals
IRWD
$586M
$1.37M 0.08%
110,532
– –
ADAG
100
Adagene
ADAG
$246M
$1.32M 0.07%
1,000,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2022 Portfolio in Review

As of Q4 2022, Artal Group held 146 positions worth $1.79B, down 24% from $2.34B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group withdrew a net $341M in Q4 2022, closing 17 positions and reducing 12 holdings. Its most notable exit was argenx, an estimated $53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Real Estate.

Against the trend, Artal Group opened a new position in Revolution Medicines worth $23.8M.

  • Artal Group's largest Q4 2022 buy was Revolution Medicines: 1,000,000 shares worth $23.8M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $32.9M increase.
  • Artal Group's biggest Q4 2022 reduction was BELLUS Health Inc., cutting an estimated $21.4M.
  • Artal Group fully exited argenx in Q4 2022, selling an estimated $53M.
  • Artal Group's ten largest holdings make up 44% of its $1.79B portfolio in Q4 2022.
  • Artal Group opened 11 new positions and closed 17 in Q4 2022.
  • Artal Group's portfolio value fell 24% quarter-over-quarter to $1.79B.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.